Actor portrayal.

Managing REMS-Certified SPRAVATO® Treatment Center Operations

Learn more about the factors that may impact how you operationalize your treatment center.

Treatment Center Space, Staffing, and Scheduling

Understand the treatment-resistant depression (TRD) and major depressive disorder with suicidal ideation (MDSI) patient populations in your community and how many appropriate patients you anticipate seeing weekly in your treatment center

Review the SPRAVATO® dosing frequency when evaluating space requirements, staffing, and scheduling

Learn more about dosing for patients with TRD and MDSI

Consider which room or designated area in your treatment center can be used as a dedicated space for patients taking SPRAVATO®, including a treatment chair where a patient can comfortably sit during the 2-hour monitoring period

Because SPRAVATO® is a Schedule III controlled substance, your treatment center will be required to store and dispose the product appropriately. Ensure that SPRAVATO® is kept in a secure place per state and federal regulations. Product dispensed by a pharmacy for a specific patient must be administered within 14 days after receipt by the treatment center

Download the SPRAVATO® Dosing and Administration Guide

Examples of how a SPRAVATO® treatment space may be set up

Multiple treatment chairs in a shared space

Multiple chairs for SPRAVATO® (esketamine) nasal spray adult patients in a shared treatment space

Single treatment chair in a dedicated space

Single chair for SPRAVATO® (esketamine) nasal spray adult patients in a dedicated treatment space

For illustrative purposes only. Not intended to represent a promise, guarantee, or legal advice by Janssen Pharmaceuticals, Inc., about practice efficiencies.

REMS=Risk Evaluation and Mitigation Strategy.